Öffentliches Studienregister des CCC-München

Studie AGO-OVAR OP.4 / DESKTOP III

Studie Studiendesign Status Ein-/Auschlusskriterien Therapie Teilnehmer Dokumente Berechtigungen Tumorboards

Studie
World
Studienakronym
:
AGO-OVAR OP.4 / DESKTOP III
World
Vollständiger Titel
:

A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery vs Chemotherapy Alone for Recurrent Platinum-Sensitive Ovarian Cancer.

World
Beschreibung
:

It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients who really benefit from surgery. Nevertheless, the AGO-score was confirmed to select patients with a less than 30% risk of ending with residual tumor after surgery for recurrent disease. This could avoid including patients into the present surgical protocol who could not benefit from an operationThe goal of this third DESKTOP study is to evaluate in a prospectively randomized multicentre setting, whether maximum effort of cytoreductive surgery followed by platinum based combination chemotherapy can improve overall survival as compared to platinum based combination chemotherapy alone in AGO-score positive patients.

World
NCT-Nr.
:
World
Zuständige Einrichtung
:
KUM - GYN - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe (Großhadern) Lmu
Krankheitsentitäten
Klassifikation Code Beschreibung
ICD-10-GM C56 Bösartige Neubildung des Ovars
Studiendesign
World
Studientyp
:
Interventionsstudie
World
Verblindungstyp
:
Offen
World
Studienphase
:
III
Status
World
Status
:
Rekrutierung beendet
Voten
World
Ethikkommission - Votum
:
Positiv
Initiierung & Abschluß
World
Abschlussdatum (Plan / Ist)
:
2016-12-01 / Unbekannt
Teilnehmer Die Studienleitung hat einer Freigabe der Kontaktdaten der Hauptprüfer bzw. Hauptansprechpartner nicht explizit zugestimmt.